Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3413189 | 0.71 | MAPT (0.47) | KMT2AMEN1HDAC6ALDH1A1CYP3A4 | |
| SCHEMBL3411481 | 0.70 | KMT2A (0.72) | KMT2AMEN1HDAC6ALDH1A1CYP3A4 | |
| SCHEMBL6285224 | 0.69 | ALDH1A1 (0.47) | KMT2AMEN1HDAC6ALDH1A1CYP3A4 | |
| SCHEMBL6284734 | 0.67 | POLB (0.42) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL3413679 | 0.66 | ALDH1A1 (0.49) | KMT2AMEN1HDAC6ALDH1A1CYP2C9 | |
| SCHEMBL6282586 | 0.66 | BCHE (0.47) | KMT2AHDAC6LMNA | |
| SCHEMBL3413674 | 0.66 | ALDH1A1 (0.49) | KMT2AMEN1HDAC6ALDH1A1CYP2C9 | |
| SCHEMBL9325925 | 0.65 | VCAM1 (0.57) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL703101 | 0.64 | TSHR (0.65) | KMT2AMEN1ALDH1A1SMN1; SMN2L3MBTL1 | |
| Hydrogen Sulfide SCHEMBL28759691 | 0.63 | TSHR (0.63) | KMT2AMEN1ALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063118-A1 | Hydantoins Having RNase Modulatory Activity | WYETH (US) | 2010-03-11 | — | — | US | claimed |
| WO-2005090316-A1 | HYDANTOINS HAVING RNase MODULATORY ACTIVITY | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050203156-A1 | Hydantoins having RNase modulatory activity | WYETH (US) | 2005-09-15 | — | — | US | claimed |
| US-20100063118-A1 | Hydantoins Having RNase Modulatory Activity | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2005090316-A1 | HYDANTOINS HAVING RNase MODULATORY ACTIVITY | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203156-A1 | Hydantoins having RNase modulatory activity | WYETH (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063118-A1 | Hydantoins Having RNase Modulatory Activity | RNASEH1, RNASE1, RNASEL | KMT2A 1205/4885MEN1 3802/4885HDAC6 572/4885 |
| US-20050203156-A1 | Hydantoins having RNase modulatory activity | RNASEH1, RNASE1, RNASEL | KMT2A 1205/4885MEN1 3802/4885HDAC6 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.